Prescription Drug Simvastatin Recalled for Manufacturing Deviations
Accord Healthcare is recalling Simvastatin 5 mg tablets distributed in the United States, Puerto Rico, and Canada. The recall follows an FDA inspection that identified manufacturing practice deviations.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is a Class II FDA recall involving manufacturing practice deviations identified during an FDA inspection. No illnesses or injuries are reported in the source, but the manufacturing quality issue represents potential risk to patient safety, meeting the rubric criterion of 'risk-of-harm products where injury has not yet been reported.'
Plain-English summary
Accord Healthcare, Inc. is recalling Simvastatin Tablets USP 5 mg in 90-count bottles (NDC 16729-156-15) and 1,000-count bottles (NDC 16729-156-17) distributed in the United States, Puerto Rico, and Canada. The recall affects approximately 256,648 bottles across multiple batch numbers with expiration dates ranging from June 2023 to May 2025.
The recall was initiated following an FDA inspection that identified deviations from current good manufacturing practice (CGMP) standards. The tablets were manufactured by Intas Pharmaceuticals Limited in Ahmedabad, India, for Accord Healthcare, Inc. in Durham, North Carolina.
Patients taking the affected Simvastatin tablets should contact their pharmacy or healthcare provider for guidance on whether their medication may be affected. Pharmacists and healthcare providers should identify and quarantine any affected product and arrange for its return or destruction.
The recalled product
- Product
- SIMVASTATIN (SIMVASTATIN)
- Brand
- SIMVASTATIN
- Manufacturer
- Accord Healthcare, Inc.
- Category
- Drug
- Hazard
- manufacturing-defect
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Batches: a) R2100818
- Exp. Date 6/30/2023
- R2100964
- R2100824
- R2100820
- R2100822
- R2101201
- Exp. Date 9/30/2023
- R2101198
- R2101199
- R2101200
- R2101355
- Exp. Date 10/31/2023
- R2200035
- R2200515
- Exp. Date 4/30/2025
- R2200514
- R2200516
- b) R2200310
- Exp Date 9/30/2023
UPCs (2)
- 316729156158
- 316729156172
Distribution
Distribution scope not specified by the agency.
Related recalls
Same brand · SIMVASTATIN
- HighSimvastatin 40 mg tablets recalled for manufacturing practice deviations
FDA (Drugs) · 2023-03-08
- ModerateSimvastatin Tablets Recalled Due to Manufacturing Practice Deviations
FDA (Drugs) · 2023-03-08
- HighAccord Healthcare Simvastatin 80 mg Tablets Recalled for Manufacturing Practice Violations
FDA (Drugs) · 2023-03-08
- ModerateSimvastatin tablets recalled due to manufacturing process deviations
FDA (Drugs) · 2023-03-08
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27